8-K: Kintara Therapeutics and TuHURA Biosciences Announce Merger Progress and Clinical Milestones

Kintara Therapeutics and TuHURA Biosciences provided an update on their merger, clinical advancements, and upcoming milestones, including a Phase 3 trial for TuHURA and continued enrollment in Kintara's REM-001 study.

Summary

• Kintara Therapeutics and TuHURA Biosciences are progressing with their merger, expected to close in the third quarter of 2024.
• Kintara's existing stockholders will own approximately 5.5% of the combined company's common stock after the merger, including a contingent value right.
• TuHURA is set to begin a Phase 3 trial for its IFx-2.0 personalized cancer vaccine in the second half of 2024.
• TuHURA has secured $31 million in financing, expected to provide cash runway into late 2025.
• Kintara received a 180-day extension until December 9, 2024, to meet Nasdaq's minimum bid price requirement.
• Kintara has dosed four patients in its REM-001 study for cutaneous metastatic breast cancer as of June 26, 2024.
• The REM-001 study is expanding to new clinical sites, including Montefiore Medical Center and the University Hospital for Albert Einstein College of Medicine.
• The majority of the REM-001 study costs are covered by a $2.0 million SBIR grant from the NIH.
• Kintara expanded the REM-001 study inclusion criteria in March 2024 to include patients receiving pembrolizumab, which is expected to accelerate enrollment.
• Kintara expects to complete enrollment and an 8-week follow-up of 10 patients in the REM-001 study by the fourth quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the merger progressing and clinical trials advancing, but there are also risks and challenges, such as the need to regain Nasdaq compliance, which temper the overall sentiment.

Positives

• The merger between Kintara and TuHURA is progressing as planned.
• TuHURA's Phase 3 trial for IFx-2.0 has the potential to be a significant advancement in cancer treatment.
• The $31 million financing provides financial stability for TuHURA into late 2025.
• Kintara's REM-001 study is advancing with patient dosing and site expansion.
• The NIH grant significantly reduces the financial burden of the REM-001 study.
• The expanded inclusion criteria for the REM-001 study should accelerate enrollment.

Negatives

• Kintara's existing stockholders will own a relatively small 5.5% of the combined company after the merger.
• Kintara needs to regain compliance with Nasdaq's minimum bid price by December 9, 2024.

Risks

• The merger is subject to various conditions, including stockholder approval, which could delay or prevent its completion.
• There are risks associated with estimating operating expenses and the impact of any delays on the combined company's cash resources.
• The success of the combined business is not guaranteed and is subject to various market and regulatory factors.
• There are risks associated with the clinical trials and the development of new therapies.
• The company faces competition and the risk of unexpected costs and expenses.

Future Outlook

The combined company expects to advance TuHURA's Phase 3 trial for IFx-2.0 and complete enrollment in Kintara's REM-001 study, while also working to regain compliance with Nasdaq listing requirements. The merger is expected to provide a cash runway into late 2025.

Management Comments

• Kintara and TuHURA provided an overview of their recent corporate and clinical advancements and outlined upcoming expected near term milestones.
• Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
• TuHURA is developing novel technologies to overcome resistance to cancer immunotherapy.

Industry Context

This announcement reflects the ongoing trend of mergers and acquisitions in the biotech industry, particularly among companies focused on oncology. The focus on personalized cancer vaccines and antibody-drug conjugates aligns with current research and development trends in the field.

Comparison to Industry Standards

• The merger of Kintara and TuHURA is similar to other strategic combinations in the biotech sector, where companies seek to leverage complementary technologies and pipelines.
• TuHURA's Phase 3 trial for IFx-2.0 is comparable to other late-stage clinical trials for cancer vaccines, such as those being conducted by companies like Moderna and BioNTech.
• Kintara's REM-001 study is similar to other early-stage clinical trials for novel cancer therapies, with a focus on safety and efficacy in a specific patient population.
• The $31 million financing secured by TuHURA is a common practice for biotech companies to fund clinical trials and operations, similar to recent financings by companies like Xencor and IGM Biosciences.

Stakeholder Impact

• Shareholders of Kintara will own a smaller percentage of the combined company, but will have exposure to TuHURA's pipeline.
• Employees of both companies will be impacted by the merger, with potential changes in roles and responsibilities.
• Patients may benefit from the development of new cancer therapies.
• Creditors and suppliers will be impacted by the financial changes resulting from the merger.

Next Steps

• Kintara and TuHURA will work to close the merger in the third quarter of 2024.
• TuHURA will commence its Phase 3 trial for IFx-2.0 in the second half of 2024.
• Kintara will continue to enroll patients in the REM-001 study and complete the 8-week follow-up by the end of 2024.
• Kintara will work to regain compliance with Nasdaq's minimum bid price requirement by December 9, 2024.

Key Dates

Keywords

Merger, Kintara Therapeutics, TuHURA Biosciences, Clinical Trial, REM-001, IFx-2.0, Cancer Vaccine, Phase 3, Nasdaq, Financing, Antibody Drug Conjugates, Merkel cell carcinoma, Cutaneous metastatic breast cancer